DATROWAY® datopotamab deruxtecan-dink 20 mg/mL INJECTION FOR INTRAVENOUS USE - A Trop-2-Directed ADC

When:  May 6, 2026 from 18:00 to 19:30 (CT)
Associated with  Southeast Minnesota

DATROWAY® datopotamab deruxtecan-dink 20 mg/mL INJECTION FOR INTRAVENOUS USE A Trop-2-Directed ADC Approved for Adults with Previously Treated Locally Advanced or Metastatic EGFR-mutated NSCLC

Program Details: 
May 6th, 2026
6:00 PM Central Standard Time
The Freighthouse Restaurant
107 Vine Street
La Crosse, WI 54601

Faculty: YAN JI, MD, PhD, MS, HealthPartners
Cancer Center at Regions Hospital

RSVP:
Rod Larson & Denise Hodgen
rodney.larson1@astrazeneca.com
(715) 572-3835

The intended audience for this program is US healthcare professionals.
This program is being provided to you by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated

Location

The Freighthouse Restaurant
107 Vine St
La Crosse, WI 54601